VBI Vaccines has reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac, the company’s trivalent hepatitis B (HBV) vaccine, and comparing safety and immunogenicity of Sci-B-Vac to GlaxoSmithKline’s currently-marketed HBV vaccine, Engerix-B.
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for a Phase 2 trial of edasalonexent, a novel NF-kB inhibitor, in non-ambulatory DMD patients.
Veristat, a full-service CRO, announced that it has completed the acquisition of The Clinical Trial Company, a global Contract Research Organization headquartered in Europe.
Exelixis announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ), Roche’s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumours.
Arcus Biosciences announced a clinical collaboration with Genentech, a member of the Roche group, for the evaluation of novel combinations with AB928, Arcus’s dual antagonist of adenosine receptors A2aR and A2bR, for colorectal (CRC) and pancreatic (PDAC) cancers.
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M. Healey & AMG Center for ALS at Mass General today announced that AMX0035 demonstrated a significant treatment benefit for people with ALS in the CENTAUR study.
Pear Therapeutics announced the first patient dosed in part II of the first clinical study evaluating Pear-006, a digital therapeutic product candidate for addressing depressive symptoms in Multiple Sclerosis (MS).
Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.
Genentech, a member of the Roche Group, announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).
Novartis announced that its asthma treatment fevipiprant has failed to meet the clinically relevant threshold in Luster phase III studies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.